Why Indian Pharma is Pivoting from Generics to Innovation

The Indian pharmaceutical sector is undergoing a structural metamorphosis, moving away from its traditional reliance on US generics toward a high-margin innovation model. According to Nandan Kulkarni, Director at Bernstein, this fundamental shift is set to redefine the industry through 2035, yet the stock market has yet to fully price in this transition.

From Generics Factory to the "Innovation Pyramid"

For decades, the valuation of Indian pharma companies was tied almost exclusively to their ability to manufacture and export off-patent generic drugs to the United States. While the generics model remains relevant, it is no longer the primary growth engine.

Kulkarni highlights an "innovation pyramid" where capital is being aggressively reallocated toward more complex and lucrative areas. Indian biopharma firms are now investing heavily in R&D, moving toward New Drug Applications (NDAs), 505(b)(2) filings, orphan drug designations, and specialty therapies. To support this, companies are hiring specialized talent across biotechnology, complex chemistry, digital health, and artificial intelligence. This shift promises significantly higher margins than the traditional generics business.

The GLP-1 Revolution and Market Dynamics

A major component of this new era is the rise of GLP-1 drugs—medications used for diabetes and obesity management. Kulkarni predicts a significant shift in the metabolic health landscape, projecting that insulin's market share could drop to approximately 50% by FY31. As GLP-1s offer superior glycemic control and weight management, they effectively defer the need for insulin.

For Indian players, this is a high-value opportunity. Historically, insulin has been a lower-margin product. A transition toward GLP-1s and peptides moves the entire value chain upward. While the adoption curve in India may be slower than in North America due to socioeconomic and dietary factors, it promises a massive, long-term grassroots penetration phase.

Beyond Policy: The Reality of "China Plus One"

While the "China Plus One" strategy has been a talking point for investors for years without significant realization, Kulkarni argues that the current landscape is different. Geopolitical tensions and the recent scrutiny surrounding companies like WuXi have moved the needle from mere policy intent to active execution.

Global innovators are now structurally realigning their supply chains to reduce dependency on China. Given India’s deep expertise in biopharma, the country is positioned as a natural and necessary beneficiary of this global diversification.

The Market’s Blind Spot

The primary disconnect lies in how "the Street" (institutional investors) perceives the sector. Currently, most analysts still model Indian pharma as a chemistry and contract manufacturing story with a side of US generics. They are failing to account for the speed of the innovation pivot and the evolving quality of the talent pool. As boardroom discussions shift from "patent cliffs" to "specialty positioning," the earnings models used by investors are lagging behind the reality on the ground.

Key Takeaways